DDInter1423 DDInter1763
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Pentobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Pentobarbital {u} (Compound) downregulates {v} (Gene) GSTZ1
GSTZ1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Pentobarbital {u} (Compound) upregulates {v} (Gene) PXN
PXN {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Pentobarbital {u} (Compound) downregulates {v} (Gene) FABP5
FABP5 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Pentobarbital {u} (Compound) causes {v} (Side Effect) Somnolence
Somnolence {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Pentobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Pentobarbital {u} (Compound) downregulates {v} (Gene) GSTZ1
GSTZ1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Pentobarbital {u} (Compound) upregulates {v} (Gene) PXN
PXN {u} (Gene) interacts with {v} (Gene) IGF1R
IGF1R {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Pentobarbital (Compound) downregulates GSTZ1 (Gene) and GSTZ1 (Gene) is upregulated by Temsirolimus (Compound)
Pentobarbital (Compound) upregulates PXN (Gene) and PXN (Gene) is upregulated by Temsirolimus (Compound)
Pentobarbital (Compound) downregulates FABP5 (Gene) and FABP5 (Gene) is downregulated by Temsirolimus (Compound)
Pentobarbital (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Temsirolimus (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Pentobarbital (Compound) downregulates GSTZ1 (Gene) and GSTZ1 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Pentobarbital (Compound) upregulates PXN (Gene) and PXN (Gene) interacts with IGF1R (Gene) and IGF1R (Gene) is upregulated by Temsirolimus (Compound)